Tianjin Development (00882.HK): Lisheng Pharmaceuticals' net profit of 59,155,600 yuan in the first quarter increased 27.22% year-on-year
Gelonghui, April 25 | Tianjin Development (00882.HK) announced that in the first quarter of 2024, Lisheng Pharmaceutical (002393.SZ) achieved operating income of 365 million yuan, up 8.71% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceutical) was 59,1556 million yuan, up 27.22% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceuticals) after deducting non-recurring profit and loss was 58.7736 million yuan, up 29.71% year on year; basic earnings per share were 0.32 yuan.
Revenues Tell The Story For Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) As Its Stock Soars 26%
Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. Unfor
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) 11% Gain Last Week Benefited Both Private Companies Who Own 37% as Well as Insiders
Key Insights Jiangsu Jibeier Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 2 investors hav
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological...
Huaren Pharmaceutical (300110.SZ): Bai Peng and Meng Xiangyuan were appointed as vice presidents
Huaren Pharmaceutical (300110.SZ) issued an announcement. The company will hold the 8th board meeting on April 23, 2024...
Huaren Pharmaceutical (300110.SZ) announced its 2023 annual results, with net profit of 188 million yuan, an increase of 4.03% over the previous year
Huaren Pharmaceutical (300110.SZ) announced its 2023 annual results, with operating revenue of 1,636 billion yuan, a year-on-year increase...